Collegium Acquires AZSTARYS from Corium for $650 Million
Collegium Acquires AZSTARYS from Corium for $650 million, betting the ADHD treatment is undercommercialized and projecting $60–70 million in...
Halozyme Q1 Royalties Rise 43% to $241M; 2026 Guidance Maintained
Halozyme Q1 royalties rise 43% to $241M on ENHANZE growth; 2026 guidance maintained as new licensing deals extend royalty...
Sana Biotechnology Reports 14-Month C-Peptide Production in UP421 Trial
Sana's UP421 trial shows 14 months of C-peptide production in a patient without immunosuppression, marking significant progress in islet...
SCYNEXIS Q1 2026: $72.4M Cash, SCY-770 ADPKD Program Launch Planned
SCYNEXIS launches SCY-770 ADPKD program with $72.4M cash runway. Phase 2 trial planned for Q4 2026 with efficacy readout...
Erasca, Merck Partner on ERAS-0015 and Pembrolizumab for RAS Mutations
Erasca and Merck partner on ERAS-0015 and pembrolizumab to target RAS mutations, with Merck supplying KEYTRUDA at no cost...
MoonLake Clears FDA Pre-BLA Meeting, Plans 2026 HS Drug Submission
MoonLake Clears FDA Pre-BLA Meeting with no remediation items, positioning for September 2026 HS drug submission and mid-2027 approval.
BMS, Hengrui Pharma Announce $15.2B Strategic Deal on Oncology, Immunology
BMS and Hengrui Pharma announce $15.2B strategic deal on oncology and immunology, with exclusive worldwide rights outside mainland China...
Oragenics Licenses CardioDialysis Technology for TBI Treatment
Oragenics licenses CardioDialysis technology for TBI treatment in exclusive deal involving 3.25M shares of preferred stock convertible to common.
Genmab Q1 2026 Royalties Jump 26% to $742 Million
Genmab Q1 2026 royalties jump 26% to $742 million, driven by daratumumab and ofatumumab sales from Johnson & Johnson...
Zymeworks Reports Q1 2026 Results, Awaits August FDA Decision on Zanidatamab
Zymeworks awaits August FDA decision on zanidatamab for HER2-positive gastroesophageal adenocarcinoma, with $250M milestone payment at stake.